B2B Funding in Medical Technology: Qure.ai Seeks $60 Mn for Radiology Innovations

Monday, 16 September 2024, 23:44

B2B funding is driving growth in the medtech sector, exemplified by Qure.ai, which is seeking $50-60 Mn to enhance its radiology diagnosis capabilities. This Mumbai-based startup aims to leverage artificial intelligence for improved medical imaging diagnostics, and the funding round is set to close soon. Qure.ai’s AI technology can quickly detect brain trauma and chest diseases, making significant strides in the field of radiology diagnostics.
Inc42
B2B Funding in Medical Technology: Qure.ai Seeks $60 Mn for Radiology Innovations

Qure.ai's Funding Round

Qure.ai is actively seeking to raise between $50-60 Mn in a funding exercise mainly led by Lightspeed to expand its B2B initiatives within the medical technology sector. According to recent reports, this infusion of capital may also include a secondary round alongside contributions from existing investors.

Investment and Company Background

Founded in 2016 by Pooja Rao and Prashant Warier, Qure.ai specializes in artificial intelligence-assisted diagnostics. The startup has developed algorithms that can swiftly identify critical conditions, such as brain trauma and chest diseases, from X-rays, CT scans, and MRIs in a fraction of the time traditionally required by physicians.

Investment Highlights

  • Lightspeed is anticipated to inject approximately $20-25 Mn and may purchase some secondary shares.
  • The overall funding round may conclude by this month.
  • Recent capital initiatives include a combination of primary and secondary funding for other healthtech firms, indicating a prosperous investment climate in B2B healthcare technology.

Qure.ai's ability to utilize AI for medical imaging is critical as the demand for advanced diagnostics rises within hospitals and healthcare facilities globally. As the company continues to grow, it remains backed by prominent investors like Fractal Analytics and Sequoia Capital.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe